Angion Biomedica Corp. (ANGN)
1.00
0.00 (0.00%)
At close: Jun 01, 2023, 8:00 PM
Company Description
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases.
The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung.
It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program.
The company was incorporated in 1998 and is based in Uniondale, New York.
Angion Biomedica Corp.
| Country | United States |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D. |
Contact Details
Address: 51 Charles Lindbergh Boulevard Uniondale, New York United States | |
| Website | https://www.angion.com |
Stock Details
| Ticker Symbol | ANGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001601485 |
| CUSIP Number | 03476J107 |
| ISIN Number | US03476J1079 |
| Employer ID | 11-3430072 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D. | Pres, Chief Executive Officer & Chairman |
| Gregory S. Curhan | Chief Financial Officer |
| Bruce Rich | Assistant Sec. |
| Daniel Iazzetti | Vice President of HR |
| Jennifer J. Rhodes J.D. | Executive Vice President, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Sec. |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2025 | 4 | Filing |
| Apr 09, 2025 | ARS | Filing |
| Apr 09, 2025 | DEF 14A | Filing |
| Apr 02, 2025 | 3 | Filing |
| Mar 31, 2025 | S-8 | Filing |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 07, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Mar 07, 2025 | 4 | Filing |